PEPG: PepGen Corp Price-to-Revenue Coefficient

Brandmark of PepGen Inc. (PEPG)

Diversified global supplies of biocomponents guarantee PepGen Inc. production stability. The market capitalization-to-revenue ratio reflects market sentiment dynamics, where characterizes this valuation parameter. The innovative EDO system ensures the efficient delivery of oligonucleotides into tissues. The development of unique treatments for rare pathologies paves the way for premium pricing and dominance in the neuromedicine segment.

PEPG (PepGen Inc) P/S Multiple history from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for PepGen Inc. (PEPG)

- share price and consensus valuation forecast:
Price Performance Chart pepgen.com|PEPG - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization PepGen Corp|PEPG - Total Company Value
- company book value details:
Equity per Share PepGen|PEPG - Book Capitalization|Market Cap to Net Assets Ratio pepgen.com|PEPG - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient PepGen Inc.|PEPG - Long-Term Debt to Equity|Current Liabilities to Equity pepgen.com|PEPG - Company Aggregate Debts|Debts to Book Value PepGen Corp|PEPG - Company Long-Term Debt|Current Liabilities PepGen|Critical Liquidity pepgen.com
- net income and valuation multiples indicators:
PEPG - Company Net Income|Net Profit Forecast PepGen Inc.|PEPG - P/E Multiple|Projected Price to Earnings Ratio pepgen.com|PEPG - Price/Earnings to Growth Multiple|EV/EBITDA Multiple PepGen Corp|PEPG - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year PepGen|PEPG - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months pepgen.com|PEPG - Earnings per share growth in current year|Net earnings per share change forecast for next year PepGen Inc.
- issuer revenue and sales details:
PEPG - Revenue and Sales Volume|Company Expected Sales Volume pepgen.com|PEPG - Price-to-Revenue Ratio|Future Price to Revenue PepGen Corp
General company analysis:PEPG - PepGen Inc
Core merchandise of PepGen Inc.

The P/S ratio measures the relationship between the market capitalization of PepGen Inc. (PEPG) and its annual sales volume, determining the cost of each dollar of revenue. For a biopharmaceutical business utilizing the EDO platform, this multiple reflects market expectations regarding the monetization of the RNA therapy patent perimeter. Analyzing the price-to-sales ratio allows for the identification of whether the asset is overbought or if its intellectual capital is undervalued. This price action reflects the balance between speculative demand and the actual scale of commercializing its developments.

Competitors of PepGen Inc.

BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|Price-to-Revenue Coefficient Regencell Bioscience Ltd (RGC)|AXSM - Price-to-Revenue Ratio|ACAD (ACADIA Corp) - Market Cap to Revenue Ratio|XENE: P/S Multiple|Market Cap to Revenue vikingtherapeutics.com|Market Cap to Revenue SUPN|Catalyst Pharma (CPRX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|HRMY: Price-to-Sales Ratio|P/S Multiple BHVN (Biohaven Ltd.)|amylyx.com (AMLX) - Price to Sales|TRVI - Price-to-Revenue Ratio|Price-to-Sales Ratio PRAX|AVXL: P/S Multiple|Price-to-Revenue Multiple CeriBell EEG CBLL|Price-to-Revenue Ratio Prothena Biosciences|Market Cap to Revenue Ratio ALEC (Alector Therapeutics)|P/S Multiple ANNX|OMER - Price to Sales|Neurogene Corp - Market Cap to Revenue|P/S Multiple AC Immune Inc ACIU|VYGR - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio NMRA (neumoratx.com)|Scilex (SCLX) - Price-to-Revenue Ratio|Price to Sales Tevogen Bio Holdings Inc. (TVGN)|Price-to-Revenue Ratio Alpha Cognition Inc|Cognition Therapeutics Inc. - Price-to-Sales Ratio|P/S Multiple IKT|SAVA - Price to Sales|Price-to-Revenue Ratio Assertio ASRT|COYA (Coya Therapeutics Inc) - Price-to-Sales Ratio|VistaGen Therapeutics Inc - P/S Multiple|Price-to-Revenue Multiple Ovid Therapeutics Inc. (OVID)|ABOS: P/S Multiple|Price to Sales cervomed.com (CRVO)|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Market Cap to Revenue Ratio CLNN (Clene Nanomedicine)|Market Cap to Revenue JUNS (Jupiter Neurosciences)|RLMD (Relmada Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple ANVS (Annovis Bio, Inc.)|Price-to-Revenue Coefficient Grace Therapeutics Inc (GRCE)|AIFF - Price-to-Revenue Ratio|KLTO (Klotho Neurosciences Inc) - Market Cap to Revenue Ratio|NRSN: P/S Multiple|Market Cap to Revenue Reviva Pharmaceuticals, Inc.|Market Cap to Revenue MTVA|neuraxis.com (NRXS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Helius Medical (HSDT)|PASG: Price-to-Sales Ratio|P/S Multiple NEUP (Neuphoria Therapeutics)|Minerva (NERV) - Price to Sales|ATHA - Price-to-Revenue Ratio|Price-to-Sales Ratio ADXN|ALZN: P/S Multiple|Price-to-Revenue Multiple Cyclerion Therapeutics, Inc. CYCN|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Market Cap to Revenue Ratio KTTA (Pasithea)|P/S Multiple CRGT|ATXI - Price to Sales|BrainStorm Cell Therapeutics - Market Cap to Revenue|P/S Multiple Cara Therapeutics Inc. CARA|CHRO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ELYM (Eliem Therapeutics)|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Price to Sales longboardpharma.com (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc - Price-to-Sales Ratio|P/S Multiple NRBO|SAGE - Price to Sales|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|TRVN (trevena.com) - Price-to-Sales Ratio|Vigil Neuro - P/S Multiple|Price-to-Revenue Multiple anewmeds.com (WENA)|CERE: P/S Multiple